The effect of empagliflozin on proteinuria
Phase 1
Recruiting
- Conditions
- Proteinuria.Persistent proteinuria, unspecifiedR80.1
- Registration Number
- IRCT20220405054414N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Age between 5 to 17 years old
Suffering from non-diabetic proteinuria according to the diagnosis of a nephrologist
Receiving a clinically appropriate dose of ACEIs or ARBs unless treatment is not tolerated or indicated
GFR more than 60ml/min
Exclusion Criteria
Moderate to severe liver failure
Having type 1and 2 diabetes
Sensitivity to any of the components of the drugs used
Hypotension
Receiving immunosuppressants in the last 6 months
Having Polycystic kidney disease
Poor patient compliance during medication visits
Kidney transplant
Concurrent administration of ACEIs or ARBs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in body measurement. Timepoint: baseline to 24 weeks. Method of measurement: scales.;Change in blood pressure. Timepoint: baseline to 24 weeks. Method of measurement: Pressure gauge device.;Change in eGFR. Timepoint: baseline to 24 weeks. Method of measurement: schwartz method.;Change in glycemic control. Timepoint: baseline to 24 weeks. Method of measurement: blood draw from vein.;Time to the first occurrence of urinary infection. Timepoint: baseline to 24 weeks. Method of measurement: urine analysis.;Time to first occurrence of AKI. Timepoint: baseline to 24 weeks. Method of measurement: SCr.
- Secondary Outcome Measures
Name Time Method Change from baseline in proteinuria. Timepoint: Baseline to ?? weeks. Method of measurement: Urin analysis.